Moleculin Signs a Clinical Research Agreement with Emory University for Brain Tumor in Pediatric Patients

 Moleculin Signs a Clinical Research Agreement with Emory University for Brain Tumor in Pediatric Patients

Moleculin Signs a Clinical Research Agreement with Emory University for Brain Tumor in Pediatric Patients

Shots:

  • Moleculin collaborated with Emory University to conduct P-I trial for WP1066 to treat recurrent or refractory malignant brain tumors in pediatric patients
  • The trial will be conducted at Aflac Cancer & Blood Disorders Center at Children’s Healthcare of Atlanta, with its expected recruitment in H2’19
  • WP1066 is an immuno-stimulating STAT3 inhibitor will be evaluated in P-I and is developed for targeting brain tumors, pancreatic cancer and AML

Click here to read full press release/ article | Ref: Moleculin | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post